TABLE 4.
Plaque reduction in BV-infected and HSV1-infected Vero cells and cytotoxicity in uninfected Vero cells by nucleoside analogs
| Nucleoside analog | Antiviral EC50 (μM)a (mean ± SD)
|
Cytotoxicity (CC50e [μM] [mean ± SD]) | |||
|---|---|---|---|---|---|
| BV 24105 | BV 32425 | BV E90-136 | HSV-1 F | ||
| ACV | 112 ± 65b | 118 ± 71c | 47.5 ± 24b | 1.4 ± 0.13d | >890 |
| GCV | 14.5 ± 12c | 23.5 ± 23.9d | 19.2 ± 13.7c | 0.7 ± 0.23d | 666 ± 106 |
| PCV | 17.0 ± 8.7b | 25.3 ± 13.8d | 17.3 ± 11.4c | 4.7 ± 2.1d | >790 |
| IUdR | 11.2 | 8.5 | NT | 2.8 | 6.8 ± 2.5 |
| TFT | 1.7 | 3.4 | NT | <1.7 | 50.6 ± 9.8 |
| BVdU | ≫300 | ≫300 | NT | 0.12 | >600 |
| Et-dU | 37.4 ± 20.3c | 48.0 ± 26c | 13.3 ± 14.8b | 2.1 ± 0.8d | >780 |
| CFV | 28.9 | 21.6 | NT | 14.4 | >720 |
| PFA | >500 | ca. 250 | NT | 250 | >1,000 |
| araA | 28 | 35 | NT | 7 | 38 ± 7.72 |
| HBPG | >330 | >330 | NT | 330 | >660 |
a
From single plaque reduction experiments (n = 1) run in duplicate, unless indicated otherwise. NT, not tested.
b
n = 5.
c
n = 4.
d
n = 3.
e
CC50, cytotoxic concentration of drug that reduced the viable cell number by 50%. Data were from [3H] TdR incorporation studies of subconfluent Vero cells in triplicate.